Treatment with anthelminthics during pregnancy: what gains and what risks for the mother and child?

Simple item page
dc.contributor.authorElliott, Alison M.
dc.contributor.authorNdibazza, Juliet
dc.contributor.authorMpairwe, Harriet
dc.contributor.authorMuhangi, Lawrence
dc.contributor.authorWebb, Emily L.
dc.contributor.authorKizito, Dennison
dc.contributor.authorMawa, Patrice
dc.contributor.authorTweyongyere, Robert
dc.contributor.authorMuwanga, Moses
dc.date.accessioned2022-01-30T18:29:12Z
dc.date.available2022-01-30T18:29:12Z
dc.date.issued2011
dc.description.abstractIn 1994 and 2002, respectively, the World Health Organization proposed that treatment for hookworm and schistosomiasis could be provided during pregnancy. It was hoped that this might have benefits for maternal anaemia, fetal growth and perinatal mortality; a beneficial effect on the infant response to immunization was also hypothesised. Three trials have now been conducted. Two have examined the effects of benzimidazoles; one (the Entebbe Mother and Baby Study) the effects of albendazole and praziquantel. All three were conducted in settings of high prevalence but low intensity helminth infection. Results suggest that, in such settings and given adequate provision of haematinics, the benefit of routine anthelminthics during pregnancy for maternal anaemia may be small; none of the other expected benefits has yet been demonstrated. The Entebbe Mother and Baby Study found a significant adverse effect of albendazole on the incidence of infantile eczema in the whole study population, and of praziquantel on the incidence of eczema among infants of mothers with Schistosoma mansoni. Further studies are required in settings that differ in helminth species and infection intensities. Further research is required to determine whether increased rates of infantile eczema translate to long-term susceptibility to allergy, and to explore the underlying mechanisms of these effects. The risks and benefits of routine anthelminthic treatment in antenatal clinics may need to be reconsidered.en_US
dc.identifier.citationElliott, A. M., Ndibazza, J., Mpairwe, H., Muhangi, L., Webb, E. L., Kizito, D., ... & Muwanga, M. (2011). Treatment with anthelminthics during pregnancy: what gains and what risks for the mother and child?. Parasitology, 138(12), 1499-1507. https://doi.org/10.1017/S0031182011001053en_US
dc.identifier.urihttps://doi.org/10.1017/S0031182011001053
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1629
dc.language.isoenen_US
dc.publisherParasitologyen_US
dc.subjectAnthelminthicen_US
dc.subjectPregnancyen_US
dc.subjectAlbendazoleen_US
dc.subjectPraziquantelen_US
dc.subjectHookwormen_US
dc.subjectSchistosoma mansonien_US
dc.subjectAtopic eczemaen_US
dc.subjectAnaemiaen_US
dc.titleTreatment with anthelminthics during pregnancy: what gains and what risks for the mother and child?en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
treatment-with-anthelminthics-during-pregnancy-what-gains-and-what-risks-for-the-mother-and-child.pdf
Size:
260.7 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences